Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells

被引:0
|
作者
Roostee, Suze [1 ,2 ,4 ]
Ehinger, Daniel [1 ,3 ,4 ]
Jonsson, Mats [1 ,4 ]
Phung, Bengt [1 ,4 ]
Jonsson, Goeran [1 ,4 ]
Sjodahl, Gottfrid [3 ,4 ]
Staaf, Johan [1 ,2 ,4 ]
Aine, Mattias [1 ,4 ]
机构
[1] Lund Univ, Dept Clin Sci Lund, Div Oncol, S-22381 Lund, Sweden
[2] Lund Univ, Div Translat Canc Res, Dept Lab Med, S-22381 Lund, Sweden
[3] Skane Univ Hosp, Dept Genet Pathol & Mol Diagnost, Lund, Sweden
[4] Lund Univ, Dept Translat Med, Malmo, Sweden
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; P53; PREDICTOR; PHENOTYPE; TRIALS;
D O I
10.1038/s41598-024-72306-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The tumour immune microenvironment (TIME) in breast cancer is acknowledged with an increasing role in treatment response and prognosis. With a growing number of immune markers analysed, digital image analysis may facilitate broader TIME understanding, even in single-plex IHC data. To facilitate analyses of the latter an open-source image analysis pipeline, Tissue microarray MArker Quantification (TMArQ), was developed and applied to single-plex stainings for p53, CD3, CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 antibody) in a 218-patient triple negative breast cancer (TNBC) cohort with complementary pathology scorings, clinicopathological, whole genome sequencing, and RNA-sequencing data. TMArQ's cell counts for analysed immune markers were on par with results from alternative methods and consistent with both estimates from human pathology review, different quantifications and classifications derived from RNA-sequencing as well as known prognostic patterns of immune response in TNBC. The digital cell counts demonstrated how immune markers are coexpressed in the TIME when considering TNBC molecular subtypes and DNA repair deficiency, and how combination of immune status with DNA repair deficiency status can improve the prognostic stratification in chemotherapy treated patients. These results underscore the value and potential of integrating TIME and specific tumour intrinsic alterations/phenotypes for the molecular understanding of TNBC.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
    Scarpa, Joseph R.
    Montagna, Giacomo
    Plitas, George
    Gulati, Amitabh
    Fischer, Gregory W.
    Mincer, Joshua S.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] Fat Biology in Triple-Negative Breast Cancer: Immune Regulation, Fibrosis, and Senescence
    Lee, Chae Min
    Fang, Sungsoon
    JOURNAL OF OBESITY & METABOLIC SYNDROME, 2023, 32 (04) : 312 - 321
  • [43] Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
    Karn, Thomas
    Jiang, Tingting
    Hatzis, Christos
    Saenger, Nicole
    El-Balat, Ahmed
    Rody, Achim
    Holtrich, Uwe
    Becker, Sven
    Bianchini, Giampaolo
    Pusztai, Lajos
    JAMA ONCOLOGY, 2017, 3 (12) : 1707 - 1711
  • [44] Identification of immune-related prognostic biomarkers in triple-negative breast cancer
    Song, Xiao-Qing
    Shao, Zhi-Ming
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (04)
  • [45] The Evolving Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Steiner, Meghan
    Tan, Antoinette R.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (05) : 305 - 315
  • [46] Immune checkpoint inhibition in early-stage triple-negative breast cancer
    Varma, Revati
    Wright, Matthew
    Abraham, Jame
    Kruse, Megan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (11) : 1225 - 1238
  • [47] Development of an immune-related prognostic biomarker for triple-negative breast cancer
    Zhang, Yan
    Wang, Quan
    Yang, Wei-Kang
    Wang, Yong-Si
    Zhou, Qiao
    Lin, Jie
    Wei, Xu-Xuan
    Liang, Tian
    Liu, Tongtong
    Fan, Wen-Tao
    Liang, Li
    Xu, You-Nian
    ANNALS OF MEDICINE, 2022, 54 (01) : 1212 - 1220
  • [48] Cancer stem cell markers allow for immune evasion in triple-negative breast cancer
    Hoffmann, Andrew D.
    CANCER RESEARCH, 2018, 78 (13)
  • [49] Our experience with immune checkpoint inhibitors in triple-negative breast cancer patients
    Nishio, Minako
    Kojitani, Yoshiki
    Kitashiro, Saya
    Ishiduka, Yasunobu
    Otsuka, Tomoyuki
    Nishida, Naohiro
    Fujisawa, Fumie
    Sugimoto, Naotoshi
    Yagi, Toshinari
    Souma, Ai
    Kanaoka, Haruka
    Oyamayama, Yuri
    Taniguchi, Azusa
    Nakajima, Satomi
    Seto, Yukiko
    Kusama, Hiroki
    Watanabe, Noriyuki
    Matsui, Saki
    Nakayama, Takahiro
    Kudou, Toshihiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1465 - S1465
  • [50] HDAC inhibition modulates immune checkpoint pathway in triple-negative breast cancer
    Barberio, Manuela Terranova
    Thomas, Scott
    Ali, Niwa
    Pawlowska, Nela
    Park, Jeenah
    Rosenblum, Michael D.
    Budillon, Alfredo
    Munster, Pamela N.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)